Next-gen biotherapeutics for animal health

The problem

Antibody therapeutics have transformed human medicine, but that progress hasn’t reached companion animals. Conventional antibody formats can’t access the target classes that matter most — ion channels, GPCRs, and hidden epitopes — and where biologics do exist, high cost of goods and frequent vet-administered dosing limit their reach.

The solution

Animerra pairs ultra-high-diversity mRNA display libraries with AI-assisted protein engineering to discover and optimize multifunctional VHH constructs. The platform reaches targets beyond conventional antibodies and engineers species-specific frameworks tuned for the efficacy, safety, and convenient dosing that veterinary medicine demands.

Our engagement

Anterra incubated this company.